Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 6 clinical trials
VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey (MPRINT)

investigators will perform surveys before and after pharmacogenomic testing and return of results, and before and after watching the educational video.

Accepts healthy volunteers
  • 22 Jul, 2022
  • 2 locations
Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients

This is a pragmatic clinical trial of 100 patients who self-identify as black or Latino. Patients with active prescriptions for at least 3 medications and a medication change within the past 6-months will be recruited from the University of Florida (UF) Health primary care clinics for panel-based pharmacogenetic testing. Participants …

  • 07 Jul, 2022
  • 1 location
Reduction of Adverse Drug Events and Readmissions (RADAR-PGX)

Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.

Accepts healthy volunteers
  • 27 Jul, 2022
  • 1 location
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made …

Accepts healthy volunteers
  • 22 Mar, 2022
  • 1 location
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System

medications. We will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and

  • 26 Feb, 2022
  • 2 locations
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.

  • 20 Jun, 2022
  • 5 locations